Informations sur le produit
EHOP-016 is a novel inhibitor of Toll-like receptor (TLR) signaling with anti-cancer activity. EHOP-016 specifically inhibits TLR signaling by targeting the effector proteins MyD88 and TRIF, which are essential for TLR activation. EHOP-016 has been shown to inhibit tumor growth in vitro and in vivo, including resistant breast cancer cells that have acquired resistance to other chemotherapeutic agents. EHOP-016 also has minimal toxicity in non-cancerous tissues and does not elicit an inflammatory response.